Oryzon Genomics SA (MC:ORY) — Market Cap & Net Worth
Market Cap & Net Worth: Oryzon Genomics SA (ORY)
Oryzon Genomics SA (MC:ORY) has a market capitalization of $227.73 Million (€194.79 Million) as of May 7, 2026. Listed on the MC stock exchange, this Spain-based company holds position #16083 globally and #103 in its home market, demonstrating a -2.06% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Oryzon Genomics SA's stock price €2.75 by its total outstanding shares 77513039 (77.51 Million). Analyse ORY cash generation efficiency to see how efficiently the company converts income to cash.
Oryzon Genomics SA Market Cap History: 2015 to 2026
Oryzon Genomics SA's market capitalization history from 2015 to 2026. Data shows change from $326.24 Million to $249.57 Million (-4.81% CAGR).
Oryzon Genomics SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Oryzon Genomics SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
17.24x
Oryzon Genomics SA's market cap is 17.24 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $394.11 Million | $735.31K | -$5.45 Million | 535.98x | N/A |
| 2017 | $236.97 Million | $16.76K | -$5.20 Million | 14135.86x | N/A |
| 2018 | $196.19 Million | $6.78 Million | -$1.18 Million | 28.93x | N/A |
| 2019 | $251.93 Million | $10.28 Million | -$3.68 Million | 24.51x | N/A |
| 2020 | $317.17 Million | $9.52 Million | -$3.40 Million | 33.31x | N/A |
| 2021 | $244.68 Million | $10.62 Million | -$4.69 Million | 23.05x | N/A |
| 2022 | $224.74 Million | $15.70 Million | -$4.23 Million | 14.32x | N/A |
| 2023 | $171.09 Million | $14.19 Million | -$3.35 Million | 12.06x | N/A |
| 2024 | $126.87 Million | $7.36 Million | -$3.67 Million | 17.24x | N/A |
Competitor Companies of ORY by Market Capitalization
Companies near Oryzon Genomics SA in the global market cap rankings as of May 7, 2026.
Key companies related to Oryzon Genomics SA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $108.50 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #357 globally with a market cap of $74.92 Billion USD.
- UCB SA (BR:UCB): Ranked #513 globally with a market cap of $51.74 Billion USD ( €44.26 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #572 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $108.50 Billion | $427.65 |
| #357 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.92 Billion | $721.05 |
| #513 | UCB SA | BR:UCB | $51.74 Billion | €236.00 |
| #572 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Oryzon Genomics SA Historical Marketcap From 2015 to 2026
Between 2015 and today, Oryzon Genomics SA's market cap moved from $326.24 Million to $ 249.57 Million, with a yearly change of -4.81%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €249.57 Million | -11.45% |
| 2025 | €281.83 Million | +122.14% |
| 2024 | €126.87 Million | -25.85% |
| 2023 | €171.09 Million | -23.87% |
| 2022 | €224.74 Million | -8.15% |
| 2021 | €244.68 Million | -22.86% |
| 2020 | €317.17 Million | +25.90% |
| 2019 | €251.93 Million | +28.41% |
| 2018 | €196.19 Million | -17.21% |
| 2017 | €236.97 Million | -39.87% |
| 2016 | €394.11 Million | +20.81% |
| 2015 | €326.24 Million | -- |
End of Day Market Cap According to Different Sources
On May 7th, 2026 the market cap of Oryzon Genomics SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $227.73 Million USD |
| MoneyControl | $227.73 Million USD |
| MarketWatch | $227.73 Million USD |
| marketcap.company | $227.73 Million USD |
| Reuters | $227.73 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Oryzon Genomics SA
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-… Read more